Related Experiment Video

Updated: Jun 10, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer

Andrew C Hsieh1, Davide Ruggero

  • 1Department of Urology, Helen Diller Family Comprehensive Cancer Center, School of Medicine, University of California, San Francisco, San Francisco, California, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|August 13, 2010
PubMed

Insights

Eukaryotic translation initiator factor 4E (eIF4E) plays a key role in cancer. New therapeutics targeting eIF4E are emerging to combat cancer progression by inhibiting its aberrant activation.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Aberrant activation of eukaryotic translation initiator factor 4E (eIF4E) is implicated in tumorigenesis.
  • eIF4E is a critical regulator of cap-dependent translation initiation.
  • Understanding eIF4E's role is crucial for developing targeted cancer therapies.

Purpose of the Study:

  • To review the general function of eIF4E in translation and cancer.
  • To present evidence linking eIF4E to cancer initiation and progression.
  • To highlight and compare emerging therapeutics targeting hyperactivated eIF4E.

Main Methods:

  • Literature review of eIF4E function in cancer.
  • Analysis of evidence for eIF4E's role in tumorigenesis.
  • Comparison of different therapeutic strategies targeting eIF4E.

Main Results:

  • eIF4E is essential for translation initiation and its dysregulation contributes to cancer.
  • Evidence supports eIF4E's involvement in both the initiation and progression of various cancers.
  • Several novel therapeutics targeting eIF4E show promise, with distinct mechanisms of action.

Conclusions:

  • Targeting eIF4E represents a promising strategy for cancer therapy.
  • Understanding the nuances of different eIF4E-targeting agents is key for effective treatment.
  • Further research into eIF4E therapeutics could lead to improved cancer outcomes.

More Related Videos

Xenopus laevis as a Model to Identify Translation Impairment10:24

Xenopus laevis as a Model to Identify Translation Impairment

Published on: September 27, 2015

Analysis of Translation Initiation During Stress Conditions by Polysome Profiling10:59

Analysis of Translation Initiation During Stress Conditions by Polysome Profiling

Published on: May 19, 2014

Related Concept Videos

Initiation of Translation02:33

Initiation of Translation

Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
Initiation of Translation02:33

Initiation of Translation

Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...